Clinical OMICS

MAY-JUN 2018

Healthcare magazine for research scientists, labs, pathologists, hospitals, cancer centers, physicians and biopharma companies providing news articles, expert interviews and videos about molecular diagnostics in precision medicine

Issue link: https://clinicalomics.epubxp.com/i/979295

Contents of this Issue

Navigation

Page 44 of 51

www.clinicalomics.com May/June 2018 Clinical OMICs 43 RPRD (Right Patient Right Drug) Diagnostics is a preci- sion medicine company offering clinical pharmacogenom- ics (PGx) testing, analysis and implementation services. RPRD's PGx tests inform drug selection and dosing to sup- port clinical decision-making, thereby improving patient outcomes through increased drug therapy effectiveness and decreased adverse reactions, with an additional benefit of reducing overall costs. The company specializes in both comprehensive PGx and tailored panels, such as the CNT Panel for identification of leukemia patients at risk for toxic- ity from thiopurine drugs. "While clinical pharmacogenom- ics (PGx) testing has been around for more than a decade, institutions have struggled with the challenges of imple- menting these services, not the least of which includes clini- cal decision and electronic medical record decision support. With practicing clinicians ourselves, RPRD understands these difficulties and has a comprehensive view of the PGx services and support required to benefit healthcare," said CEO Ulrich Broeckel, M.D. "Our staff has over 60 years of combined clinical expertise and implementation experience. RPRD is committed to science-driven research and develop- ment as well as state-of-the-art testing platforms focused on highest impact yet cost-effective solutions for our customers and their patients." RPRD also serves the pharmaceutical and clinical trials industries as a pharmacogenetics testing and data-analysis resource. Two Pore Guys is developing a portable device based on solid-state nanopore technology that detects and quantifies DNA/RNA and analyte targets in an inexpensive form fac- tor. The 2PG sample-to-answer device in development can be used for a number of applications, including liquid biop- sies, detecting and monitoring pathogens, and for agricul- tural applications. "At the heart of our technology platform is a solid-state nanopore that electrically detects single mol- ecules and discriminates targets of interest from background using our patented biochemical methods," said William Dunbar, Ph.D., acting CEO, and CTO. "Among the advan- tages of this approach is that the solution is much faster and cheaper than traditional qPCR, with accuracy matching that of ddPCR. We believe the simplicity and cost-effectiveness of this approach, combined with a portable form factor, will disrupt markets as a multi-omcis platform." Headquarters: Milwaukee, WI. Year Founded: 2016. Company Founders: Ulrich Broeck- el, M.D., CEO; Carter Cliff, director. Employees: 10. Major Investors: Children's Hospital of Minnesota. As a B-to-B-to-freemium-consumer play, Root helps institu- tions engage the world's largest living cohort of engaged, contactable, well genotyped people, by giving more than 29 million tissue-donor volunteers their own prismatically informative HLA data—securely and well interpreted—to use in life and for science. "As a genomicist who lost my mom young, to a blood cancer with no marrow donor, I know first-hand how our most diverse and prismatically informative genes, HLA, bond humanity together," said Founder Nathan Pearson, Ph.D. "But with no one offering good personal insight from HLA, I saw that doing so— clearly, brightly, wisely, and free—could help millions learn and thrive from the genes that say more, for each person and for science, than any other DNA." Headquarters: Boston. Year Founded: 2016. Company Founder: Nathan Pearson, Ph.D. Employees: 4. Major Investors: pre-seed. Headquarters: Santa Cruz, CA. Year Founded: 2011. Company Founders: William Dun- bar, Ph.D., acting CEO and CTO; Trevor Morin, Ph.D., CSO; Dan Heller, strategic advisor and board member. Employees: Undisclosed. Major Investors: Khosla Ventures. Arthead- / Getty Images

Articles in this issue

Links on this page

Archives of this issue

view archives of Clinical OMICS - MAY-JUN 2018